Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RADHA MENON

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1427218122
CMS profile
109774
Location
HIGH POINT, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$1,553.61

84 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,531.45 83
Education $22.16 1

By paying entity

PY2023 · entire year · sorted by reported total

Page 2 of 2; records 51–84 of 84 matching records. This page contains 34 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RADHA MENON

NPI 1427218122 · CMS profile ID 109774

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

HIGH POINT, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–84 of 84 matching records. This page contains 34 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1427218122?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RADHA MENON, NPI 1427218122, CMS profile ID 109774. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–84 of 84 matching records. This page contains 34 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1427218122?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). RADHA MENON, NPI 1427218122, CMS profile ID 109774. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–84 of 84 matching records. This page contains 34 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1427218122?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
RADHA MENON, NPI 1427218122, CMS profile ID 109774, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–84 of 84 matching records. This page contains 34 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1427218122?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

84 matching records · $1,553.61 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 84 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–84 of 84.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Ironwood Pharmaceuticals, Inc $14.0605/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1045554087 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $12.0205/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057409285 CMS
INTERCEPT PHARMACEUTICALS, INC. $20.3005/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053829955 CMS
ABBVIE INC. $12.7705/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997903695 CMS
Celgene Corporation $20.3205/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014817399 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $15.4905/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057309513 CMS
NESTLE HEALTHCARE NUTRITION INC. $13.8605/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012470479 CMS
ABBVIE INC. $16.4004/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997903693 CMS
Celgene Corporation $7.0904/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014817389 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $13.7704/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057161831 CMS
ABBVIE INC. $15.6904/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997903691 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $17.7704/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057065467 CMS
GENZYME CORPORATION $22.0104/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050095743 CMS
ABBVIE INC. $13.1104/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997903689 CMS
ABBVIE INC. $11.6103/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997903687 CMS
Regeneron Healthcare Solutions, Inc. $22.1603/22/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999299927 CMS
Regeneron Healthcare Solutions, Inc. $31.9003/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999299933 CMS
Daiichi Sankyo Inc. $23.5803/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006366349 CMS
ABBVIE INC. $7.3903/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997903685 CMS
Janssen Biotech, Inc. $21.8403/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988321567 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $0.2103/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057305565 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $13.7703/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057364623 CMS
Celgene Corporation $20.2403/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014817319 CMS
Gilead Sciences, Inc. $16.2202/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025955777 CMS
ABBVIE INC. $17.8102/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997903683 CMS
IDORSIA PHARMACEUTICALS US INC $14.3202/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034421125 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $22.8502/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057257769 CMS
GENZYME CORPORATION $18.1802/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050095723 CMS
ABBVIE INC. $9.4202/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997903681 CMS
Gilead Sciences, Inc. $20.1801/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025809463 CMS
Takeda Pharmaceuticals U.S.A., Inc. $26.6701/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055488947 CMS
Celgene Corporation $15.3801/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014817281 CMS
ABBVIE INC. $19.6901/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997903679 CMS
INTERCEPT PHARMACEUTICALS, INC. $16.3801/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053829951 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $981.94 60
PY2020 $316.13 17
PY2021 $967.68 69
PY2022 $1,539.62 90
PY2023 $1,553.61 84
PY2024 $1,637.69 86
PY2025 $1,365.44 77

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2024 Principal investigator $1,293,718.70 230

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

230 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 12/31/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120204886
Principal investigator 1 Braintree Laboratories, Inc. $95,699.70 12/31/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120205024
Principal investigator 1 Braintree Laboratories, Inc. $20,650.00 12/31/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120205026
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 12/25/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120204786
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 12/25/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120204818
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 12/25/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120204820
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 12/25/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120204822
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 12/18/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120204630
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 12/18/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120204632
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 12/18/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120204634
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 12/18/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120204760
Principal investigator 1 Braintree Laboratories, Inc. $41,300.00 12/18/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120204762
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 12/18/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120204764
Principal investigator 1 Braintree Laboratories, Inc. $8,260.00 12/18/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120204766
Principal investigator 1 Braintree Laboratories, Inc. $72,000.00 12/10/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120204574
Principal investigator 1 Braintree Laboratories, Inc. $33,040.00 12/06/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120204486
Principal investigator 1 Braintree Laboratories, Inc. $49,560.00 12/02/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120204466
Principal investigator 1 Braintree Laboratories, Inc. $16,520.00 11/20/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120204408
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 11/14/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120204158
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 11/14/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120204160
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 11/14/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120204162
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 11/14/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120204164
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 11/14/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120204168
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 11/14/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120204170
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 11/14/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120204172
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 11/14/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120204174
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 11/14/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120204176
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 11/14/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120204178
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 11/14/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120204280
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 11/14/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120204282
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 11/14/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120204284
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 11/14/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120204286
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 11/14/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120204288
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 11/14/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120204290
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 11/14/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120204292
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 11/14/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120204294
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 11/14/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120204296
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 11/14/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120204298
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 11/13/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120204098
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 11/13/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120204100
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 11/13/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120204102
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 11/13/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120204104
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 11/13/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120204106
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 11/13/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120204108
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 11/13/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120204110
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 11/13/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120204112
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 11/13/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120204114
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 11/13/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120204116
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 11/13/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120204118
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 11/13/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120204140
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 11/13/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120204142
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 11/13/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120204144
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 11/13/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120204146
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 11/13/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120204148
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 11/13/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120204150
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 11/13/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120204152
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 11/13/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120204154
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 11/13/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120204156
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 11/12/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203994
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 11/12/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203996
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 11/12/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203998
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 11/12/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120204002
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 11/12/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120204004
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 11/12/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120204006
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 11/12/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120204084
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 11/12/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120204086
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 11/12/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120204088
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 11/12/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120204092
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 11/12/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120204094
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/29/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203450
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/29/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203452
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/29/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203454
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/29/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203456
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/29/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203458
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/29/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203460
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/29/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203462
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/29/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203464
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/29/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203466
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/29/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203468
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/29/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203470
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/29/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203472
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/29/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203474
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/29/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203478
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/29/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203480
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/29/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203482
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/29/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203484
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/29/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203486
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/29/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203488
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/29/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203490
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/29/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203492
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/29/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203494
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/29/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203496
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/29/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203498
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/29/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203500
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/29/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203502
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/29/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203504
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/29/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203506
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/29/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203860
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/29/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203862
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/29/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203864
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/29/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203866
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/29/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203868
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/29/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203870
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/29/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203872
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/29/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203874
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/29/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203876
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/29/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203878
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/29/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203880
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/29/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203882
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/29/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203884
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/29/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203888
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/29/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203890
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/29/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203892
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/29/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203894
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/29/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203896
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/29/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203898
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/29/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203900
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/29/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203902
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/29/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203904
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/29/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203906
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/29/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203910
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/29/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203912
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/29/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203914
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/29/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203916
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/29/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203918
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/29/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203920
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/29/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203922
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/29/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203924
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/29/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203926
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/14/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203188
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/14/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203204
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/14/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203206
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/14/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203208
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/14/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203210
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/11/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203140
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/11/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203142
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/11/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203176
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/11/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203178
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/11/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203180
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/11/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203182
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/11/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203184
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/08/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203034
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/08/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203036
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/08/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203038
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/08/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203040
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/08/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203042
Principal investigator 1 Braintree Laboratories, Inc. $37,689.00 10/08/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203044
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/08/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203098
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/08/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203100
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/08/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203102
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/08/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203104
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/08/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203106
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/08/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203108
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/08/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203110
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/08/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203112
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/08/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203114
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/08/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203116
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/08/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203118
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/08/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203120
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/08/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203122
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/08/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203124
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/04/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120202986
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/04/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120202988
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/04/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120202990
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/04/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203014
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/04/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203016
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/04/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203018
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/04/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203020
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/04/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203022
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/04/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203024
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/04/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203026
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/03/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120202788
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/03/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120202790
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/03/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120202792
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/03/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120202794
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 10/03/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120202946
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 09/30/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120202704
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 09/30/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120202706
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 09/30/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120202708
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 09/30/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120202710
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 09/30/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120202712
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 09/30/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120202714
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 09/30/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120202782
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 09/30/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120202784
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 09/27/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120202662
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 09/27/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120202664
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 09/27/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120202672
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 09/27/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120202674
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 09/25/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120202610
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 09/25/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120202654
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 09/25/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120202656
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 09/25/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120202658
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 09/19/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120202206
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 09/19/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120202208
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 09/19/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120202210
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 09/19/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120202212
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 09/19/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120202214
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 09/19/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120202216
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 09/19/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120202218
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 09/19/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120202220
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 09/19/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120202222
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 09/19/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120202224
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 09/19/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120202226
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 09/19/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120202228
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 09/19/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120202356
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 09/19/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120202358
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 09/19/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120202360
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 09/19/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120202362
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 09/19/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120202364
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 09/19/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120202366
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 09/19/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120202368
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 09/19/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120202370
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 09/19/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120202372
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 08/28/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120201932
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 08/14/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120201632
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 07/31/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120201310
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 07/31/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120201442
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 06/19/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH LLC
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120200570
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 06/19/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH LLC
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120200572
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 06/19/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH LLC
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120200574
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 06/19/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH LLC
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120200576
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 06/19/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH LLC
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120200578
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 06/19/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH LLC
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120200584
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 06/19/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH LLC
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120200588
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 06/19/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH LLC
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120200590
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 06/19/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH LLC
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120200592
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 06/19/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH LLC
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120200594
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 06/19/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH LLC
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120200596
Principal investigator 1 Braintree Laboratories, Inc. $4,130.00 06/19/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH LLC
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120200598
Principal investigator 1 Braintree Laboratories, Inc. $10,400.00 03/27/2024 Non-covered Recipient Entity
PETERS MEDICAL RESEARCH LLC
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120199514